NCT02486562 IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
| NCT ID | NCT02486562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Accelerated Cure Project for Multiple Sclerosis |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2014-11 |
| Primary Completion | 2030-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2014-11 with a primary completion date of 2030-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
iConquerMS™ is a research initiative developed by and for people with multiple sclerosis (MS) to contribute their health data and ideas to advance and accelerate research into MS. iConquerMS welcomes adults with MS and others interested in advancing MS research, children and teens with MS and their family members (via iConquerMS Kids \& Teens) and MS caregivers (via iConquerMS Caregivers) to participate.
Eligibility Criteria
Inclusion Criteria: * 21 years of age or older at the time of informed consent or under 21 with parental consent and participant assent. Exclusion Criteria: * Unwilling or unable to provide informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02486562 clinical trial?
This trial is open to participants of all sexes, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02486562 currently recruiting?
Yes, NCT02486562 is actively recruiting participants. Contact the research team at sloud@acceleratedcure.org for enrollment information.
Where is the NCT02486562 trial being conducted?
This trial is being conducted at Waltham, United States.
Who is sponsoring the NCT02486562 clinical trial?
NCT02486562 is sponsored by Accelerated Cure Project for Multiple Sclerosis. The trial plans to enroll 20,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.